InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
63,062.64
(
-0.50%
)
Post# of 43360
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Fezziwig2008

Send PM Follow Ignore
Followers 24
Posts 501
Boards Moderated 1
Alias Born 03/09/2014

Fezziwig2008

Re: None

Saturday, 10/17/2020 8:51:06 AM

Saturday, October 17, 2020 8:51:06 AM

Post# of 43360
GILD and Open Label CAR-T Lenzilumab Data- Key to M&A -
Remdesivir Fail in huge WHO trial will focus GILD attention on its partner in “Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)“ more sharply - this is Open Label Data - certainly the better it is the more impetus GILD has to buy its partner and expand into Treatment of ARDS in Covid.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up